Sartorius (FRA:SRT3) received a €97.00 ($119.75) price target from investment analysts at UBS Group in a research report issued on Wednesday. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price objective would suggest a potential downside of 3.19% from the stock’s current price.
Several other research firms have also recently issued reports on SRT3. Deutsche Bank set a €90.00 ($111.11) target price on shares of Sartorius and gave the company a “neutral” rating in a research note on Thursday, February 1st. Nord/LB set a €75.00 ($92.59) price objective on shares of Sartorius and gave the stock a “sell” rating in a research report on Friday, February 2nd. HSBC set a €86.00 ($106.17) price objective on shares of Sartorius and gave the stock a “neutral” rating in a research report on Wednesday, February 7th. Warburg Research set a €90.00 ($111.11) price objective on shares of Sartorius and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Berenberg Bank set a €85.00 ($104.94) price objective on shares of Sartorius and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of €80.64 ($99.55).
Sartorius (SRT3) opened at €100.20 ($123.70) on Wednesday. Sartorius has a 12 month low of €67.61 ($83.47) and a 12 month high of €100.20 ($123.70). The stock has a market cap of $7,270.00 and a price-to-earnings ratio of 81.46.
COPYRIGHT VIOLATION NOTICE: “Sartorius (SRT3) Given a €97.00 Price Target by UBS Group Analysts” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/16/sartorius-srt3-given-a-97-00-price-target-by-ubs-group-analysts.html.
Sartorius Aktiengesellschaft provides laboratory and process technologies and equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.